All In Biotech

Drug Trial Radar · NCT07114055

Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 15, 2025

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Md. Hazrat AliAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS. It will also assess about the safety of drugs ebastine and placebo by recording the patient reported adverse events. The main questions it aim to answer are: Does drug ebastine and placebo has any effect on patients with IBS-D? What medical problems do participants have when taking drug ebastine and placebo? Researcher will compare effect of drug ebastine and placebo . Participant will: Take drug ebastine 20 mg at night and placebo once daily at night every day for 8 weeks along with lifestyle modifications. After that all two groups will visit the hospital 4 weekly, and their symptoms will be assessed by IBS symptom severity score (IBS-SSS) at baseline, week 4 and week 8. Additionally, patient reported adverse events will be documented.

Conditions

  • Irritable Bowel Syndrome - Diarrhoea

Interventions

  • ebastineDrug

    Tab. Ebastine 20mg once daily at night

  • PlaceboDrug

    Tab. Placebo once daily at night

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Improvement of diarrhea predominant IBS symptomsTime frame: [At baseline before randomization and then at week 4, and 8 ]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dhaka Medical College

    Dhaka, Bangladesh · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.